logo
I'm a Dietitian. This Is the One Food I'm Trying to Eat More Often

I'm a Dietitian. This Is the One Food I'm Trying to Eat More Often

Yahoo9 hours ago
As a dietitian, I'm not one to overhype any particular food for its nutritional benefits, but there is one humble pantry staple I'm personally trying to eat more often: beans.
Whether they're canned, dried, or sneakily blended into soups, salads, or dips, beans are packed with powerful nutrients and offer some of the biggest health payoffs for the lowest cost and effort. Yet despite all they offer, they're seriously under-consumed in most American diets.
Let's discuss the science behind why I'm working to include them more often, and why you should too.The Dietary Guidelines recommend that adults consume about 1.5 cups of legumes per week, which can be divided into a half-cup serving three times a week. That's not much, but most of us still fall short.
Eating beans also helps increase fiber, plant-based protein, and nutrients like potassium and B vitamins. Additionally, nearly 9 out of 10 Americans fail to meet the recommended fiber intake, which is 25 grams per day for women and 38 grams for men. Beans happen to be one of the richest sources of both soluble and insoluble fiber. And eating enough fiber supports better digestive health, regulates your blood sugar, and keeps you feeling full.
You can think of fiber like the 'broom' that comes in to sweep out your gut, clearing out toxins, binding waste, and helping excrete excess hormones and cholesterol. Plus, eating enough fiber helps digestion run smoothly and keeps you regular.As a dietitian, I already knew beans were good for you. But lately, I've been more intentional about eating them regularly, and here's why:
One of the biggest reasons I've been reaching for more beans is their impressive fiber content in a serving, especially soluble fiber. Soluble fiber dissolves in water and forms a gel-like substance in the digestive tract, which helps lower LDL ('bad') cholesterol, slows the absorption of sugar, and feeds beneficial gut bacteria. This can have a powerful impact on heart health, blood sugar control, and digestive regularity.
A half-cup of black beans delivers around 7 to 8 grams of fiber, putting a major dent in the recommended 25 to 38 grams per day. Research shows that diets high in fiber are linked to lower risks of cardiovascular disease, type 2 diabetes, and colorectal cancer, yet most of us are still falling far short. Eating beans regularly is a simple and effective way to close that gap.
Beans are also a fantastic source of plant-based protein, with 7 to 9 grams per half-cup cooked serving, depending on the variety. This makes them especially valuable for vegetarians, vegans, or anyone looking to reduce their intake of animal protein. But it's not just about protein quantity, it's also about the total impact on health.
Studies have shown that replacing animal proteins with plant proteins like those found in legumes is associated with a lower risk of heart disease, type 2 diabetes, and even some cancers. Plus, plant-based proteins tend to come bundled with beneficial nutrients like fiber and antioxidants, rather than the saturated fat or cholesterol found in some animal products. Beans can help you boost your protein intake while supporting your long-term health goals.
Beans may not get the same spotlight as trendy superfoods, but they're nutrient-dense powerhouses. In addition to fiber and protein, they contain a wide range of essential nutrients many Americans don't get enough of—including folate, magnesium, potassium, iron, and B vitamins. They're also rich in polyphenols and antioxidants, which help combat oxidative stress and inflammation.
These nutrients play a key role in everything from energy metabolism and red blood cell formation to nerve function and muscle health. Potassium, for example, helps balance sodium and support healthy blood pressure. Yet it's one of the most commonly under-consumed nutrients in the U.S. In fact, it's been labeled a 'nutrient of concern' for Americans. Beans offer a budget-friendly, accessible way to fill those nutrient gaps and support whole-body health.If you're not used to eating beans, start small. And if you're new to beans and concerned about bloating, try lentils or split peas first, and gradually increase your intake while drinking plenty of water. All legumes count here — some of the most common legumes you'll find at the store include black beans, chickpeas, lentils, kidney beans, pinto beans, and edamame.
Here are a few easy, non-intimidating ways to get more into your meals:
Toss them into salads or grain bowls for a satisfying boost.
Blend into dips like hummus or white bean spread.
Stir into pasta sauces or taco meat to stretch your protein.
Add them to soups or stews for extra protein and fiber.
Try bean-based snacks, like roasted chickpeas or lentil chips.
Use canned beans for convenience and choose low-sodium or give them a rinse if you are looking for a low-salt option.
Beans may be small, but their impact on health can be mighty. From fiber and protein to key vitamins and minerals, they deliver health benefits in every bite, like supporting heart health, gut health, blood sugar balance, and more. As a dietitian, I'm always looking for simple, easy ways to improve my own nutrition and help others do the same—and beans fit the bill perfectly. No matter how you enjoy them, adding more beans to your routine is a smart, satisfying step toward better health.
I'm a Dietitian. This Is the One Food I'm Trying to Eat More Often first appeared on Men's Journal on Jul 4, 2025
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment
Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment

Yahoo

timean hour ago

  • Yahoo

Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment

Edgewise Therapeutics Inc. (NASDAQ:EWTX) is one of the best up and coming stocks to invest in now. On June 26, Edgewise Therapeutics announced positive results from its sevasemten program for Becker and Duchenne muscular dystrophies. For Becker muscular dystrophy, the company reported positive data from MESA, which is an open-label extension trial that provides continued access to sevasemten for participants previously enrolled in ARCH, CANYON, GRAND CANYON, or DUNE trials. Sevasemten maintained a favorable safety profile over up to 3 years of treatment. For Duchenne muscular dystrophy, Edgewise announced encouraging topline data from its Phase 2 LYNX and FOX trials. A scientist in a lab coat using a microscope to study a cultured biopharmaceutical product. Sevasemten is an orally administered and first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies like Becker and Duchenne. Becker muscular dystrophy is a rare, genetic, debilitating, and degenerative neuromuscular disorder primarily affecting males, with no currently approved therapies. Duchenne muscular dystrophy is a severe degenerative muscle disorder, the most common type of muscular dystrophy, with a median life expectancy of around 30 years. Edgewise Therapeutics Inc. (NASDAQ:EWTX) is a biopharmaceutical company that discovers, develops, and commercializes therapies for the treatment of muscle disorders. While we acknowledge the potential of EWTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas
Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas

Yahoo

time2 hours ago

  • Yahoo

Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas

Abbott Laboratories (NYSE:ABT) is one of the high profit margin stocks to buy now. On June 19, Beta Bionics Inc. (NASDAQ:BBNX) announced its plan to integrate its iLet Bionic Pancreas automated insulin delivery/AID system with Abbott's future dual glucose-ketone sensor in the US. The collaboration aims to enhance real-time decision-making support for individuals with diabetes. The iLet Bionic Pancreas received FDA clearance in May 2023 and is distinguished as the first and only AID system that autonomously makes 100% of insulin dosing decisions. This eliminates the need for carb counting or manual insulin correction calculations for users, though they still need to be 'carb aware.' The system currently supports Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor, and the new agreement deepens the ongoing partnership between Beta Bionics and Abbott. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The new dual sensor is currently under development and is built on the same form factor as Abbott's FreeStyle Libre 3 Plus and will continuously monitor both glucose and ketone levels. Ketone monitoring is a crucial advancement as it can help detect early signs of diabetic ketoacidosis, which is a serious complication of diabetes. Abbott's dual glucose-ketone sensor has received FDA breakthrough device designation. Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells health care products. Beta Bionics Inc. (NASDAQ:BBNX) is a commercial-stage medical device company. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies
BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies

Yahoo

time3 hours ago

  • Yahoo

BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies

BrightSpring Health Services Inc. (NASDAQ:BTSG) is one of the best new stocks to buy now. On June 18, BrightSpring Health Services announced that its specialty pharmacy, called Onco360, has been chosen as the national pharmacy partner for several newly approved therapies. These innovative treatments target advanced cancers and rare genetic disorders. BrightSpring delivers care and clinical solutions to 400,000+ customers, clients, and patients daily across all 50 states. Onco360 will provide access, education, data, and expert support for patients suffering from advanced ovarian and lung cancers, as well as neurofibromatosis type 1. A medical technician using surgical robotics to perform minimally-invasive urologic surgery in an operating room. Onco360 has been selected as a pharmacy partner for the following specific medication therapies: GOMEKLI, which is approved for adult and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas/PN not suitable for complete resection; AVMAPKI FAKZYNJA CO-PACK, which is approved for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer/LGSOC who have received prior systemic therapy; and IBTROZI, which is approved for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). BrightSpring Health Services Inc. (NASDAQ:BTSG) is a home and community-based healthcare services platform in the US that operates through 2 segments: Pharmacy Solutions and Provider Services. Onco360 is a national, independent Oncology Pharmacy and clinical support services company. While we acknowledge the potential of BTSG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store